Resectable non-small-cell lung cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. According to the 8th edition AJCC staging criteria, it is stage II-IIIB and determined by thoracic surgery specialists (after multi-disciplinary team consultation as per institutional practice) that the lesion is resectable. 2. Age >= 18 years old. 3. ECOG performance status score of 0-1. 4. Baseline imaging examination shows at least one measurable lesion according to RECIST v1.1 criteria. 5. Plan to use PD-1/PD-L1 inhibitor combined with chemotherapy as the first-line neoadjuvant treatment. 6. Organ and bone marrow functions meet the institutional standards and are safe for treatment. 7. Sign the informed consent form before the trial. 8. Histological or cytological confirmed, untreated NSCLC.
Exclusion criteria
Exclusion criteria: 1. There are targetable genetic mutations such as EGFR exon 19 deletion or exon 21 L858R mutation, ALK fusion or ROS1 fusion. 2. Currently suffering from other types of malignant tumors or having a history of malignant tumors within the past 10 years. 3. Currently participating in other clinical trials that may interfere with the assessment results of this study. 4. Currently suffering from acute or chronic mental disorders or having cognitive dysfunction. 5. Currently receiving antidepressant/anxiety medication treatment or having received psychological treatment within the past 6 months. 6. Used systemic corticosteroids continuously within 1 month before the baseline assessment (except for physiological replacement doses). 7. Have active infections, active or refractory autoimmune diseases, uncontrolled systemic diseases, etc. that may affect the assessment results or increase risks. 8. Unable to cooperate or complete the scale assessment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hospital Anxiety and Depression Scale score; | — |
Countries
China
Contacts
Fujian Medical University Union Hospital